Lactobacillus mali APS1 Probiotic for Metabolic Syndrome Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for metabolic syndrome, particularly obesity and type 2 diabetes, are inadequate, with a lack of effective medical interventions beyond diet control and exercise, and there is a need for a solution that addresses the underlying inflammatory and metabolic dysregulation associated with these conditions.

Innovation Solution

The use of Lactobacillus mali APS1, a specific strain of probiotic bacteria, which is isolated and deposited under DSMZ Accession No. DSM 32117, is proposed as a pharmaceutical composition or dietary supplement to prevent or treat metabolic syndrome by improving body weight, glucose tolerance, and reducing cholesterol levels, thereby addressing insulin resistance and inflammation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional diet control and exercise are used to treat metabolic syndrome, then treatment cost is low, but treatment effectiveness is insufficient

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent introduces Lactobacillus mali APS1 as a biological intermediary agent to mediate between the host and metabolic syndrome pathology. This probiotic strain acts as a mediator that modulates intestinal microbiota composition, reduces inflammation, and improves metabolic parameters, thereby enhancing treatment effectiveness beyond conventional diet and exercise alone

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the biological parameter of intestinal microbiota composition by introducing a specific probiotic strain. This parameter change leads to cascading effects including reduced pro-inflammatory cytokines, improved insulin sensitivity, and better glucose metabolism, thereby resolving the treatment effectiveness limitation

Inventive Principle:

Principle #35Parameter changes

2Reliability

If probiotics are used to improve metabolic symptoms, then glucose tolerance and insulin sensitivity are improved, but the specific effective strain was not identified

Engineering Contradiction:

Improvemetabolic improvement efficacyVSAvoidstrain identification difficulty

Core Design Contradiction:

ReliabilityVSDifficulty of detecting and measuring

Solution Approach 1:

The patent segments the broad probiotic category into specific strains by isolating and characterizing Lactobacillus mali APS1 from fermented food. This segmentation approach identifies the particular strain responsible for metabolic improvements, resolving the difficulty of strain identification and enabling targeted therapeutic application

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent replaces the trial-and-error approach of probiotic selection with a systematic isolation and identification method. By using cultural characteristics, morphological features, and physiological properties to identify L. mali APS1, the patent substitutes random selection with a structured identification system

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Reliability

If intestinal microbiota composition is altered to treat obesity, then energy metabolism and inflammation are regulated, but the mechanism is not fully understood

Engineering Contradiction:

Improvemetabolic regulation effectivenessVSAvoidmechanism understanding

Core Design Contradiction:

ReliabilityVSLoss of information

Solution Approach 1:

The patent establishes a feedback mechanism where Lactobacillus mali APS1 modulates intestinal microbiota, which in turn regulates host metabolism and inflammation. The patent documents the feedback loop between probiotic administration, microbiota composition changes, and metabolic parameter improvements, reducing the loss of mechanistic information

Inventive Principle:

Principle #23Feedback

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Lactobacillus mali APS1 significantly reduces body weight, inhibits weight gain, improves glucose tolerance, and decreases levels of glucose, total cholesterol, and triglycerides, while increasing incretin levels, effectively alleviating symptoms of obesity and diabetes.

Implementation Method 1

The composition is effective in regulating the composition of intestinal microbiota in the host, so that the ratio of Gram positive/negative bacteria in the host is adjusted

Methodology Applied

Scientific EffectProbiotic modulation of intestinal microbiota:

Implementation Method 2

The composition is effective in reducing the production of pro-inflammatory cytokines and chemokines produced by macrophages infiltration under the condition of visceral fat accumulation

Methodology Applied

Scientific EffectAnti-inflammatory effect through cytokine reduction:

Implementation Method 3

The composition is effective in improving the glucose metabolism and the insulin sensitivity of the host

Methodology Applied

Scientific EffectGlucose metabolism regulation:

Implementation Method 4

The composition is effective in improving the lipid metabolism of the host, in particular the total cholesterol level and the triglyceride level in the blood of the host are reduced

Methodology Applied

Scientific EffectLipid metabolism regulation:

Data Source

PatentUS9884079B2Biologically pure <i>Lactobacillus mali </i>strain and composition thereof for treating metabolic syndrome

Publication Date: 2018.02.06 NAT TAIWAN UNIV

AI summary

A Lactobacillus mali strain that can be used for treating a metabolic syndrome is provided. A method for treating obesity, diabetes or a complication of diabetes by using the Lactobacillus mali strain is also provided.